NCT04430738 2026-02-24
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
Seagen Inc.
Phase 2 Active not recruiting
Clinical Trials
126 trialsNCT07229846 2026-01-08
A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation
Harbin Medical University
Phase 2 Not yet recruiting
NCT07281768 2025-12-15
Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Not yet recruiting
NCT07243938 2025-11-24
Phase II Basket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET)
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Not yet recruiting
NCT03984578 2025-11-18
Window of Opportunity Study in Colorectal Cancer
National Cancer Centre, Singapore
Phase 2 Completed
NCT07233850 2025-11-18
A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers
Shenyang Sunshine Pharmaceutical Co., LTD.
Phase 2 Not yet recruiting
NCT05382442 2025-10-14
A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer
Akeso
Phase 2 Active not recruiting
NCT03929666 2025-09-12
A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
Jazz Pharmaceuticals
Phase 2 Completed
NCT02978612 2025-09-05
ACE
Oslo University Hospital
Phase 2 Completed
NCT05489211 2025-07-11
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
AstraZeneca
Phase 2 Recruiting
NCT06991465 2025-05-28
Hypo-OPRA
McGill University Health Centre/Research Institute of the McGill University Health Centre
Phase 2 Recruiting
NCT04245865 2025-04-27
Toco-CoR
Vejle Hospital
Phase 2 Active not recruiting
NCT06888843 2025-03-27
AHTCRR-1
Nizhny Novgorod Regional Clinical Oncology Center
Phase 2 Recruiting
NCT03396926 2025-02-28
Pembrolizumab, Capecitabine, and Bevacizumab for Treating Colorectal Cancer
University of California, San Francisco
Phase 2 Completed
NCT00961571 2025-02-12
Sunitinib and Capecitabine for First Line Colon Cancer
Georgetown University
Phase 2 Terminated
NCT01531595 2024-12-12
AXOAXI
Helsinki University Central Hospital
Phase 2 Active not recruiting
NCT06405139 2024-11-29
Nanoliposomal Irinotecan, Oxaliplatin Plus Capecitabine As Conversion Therapy of Locally Advanced Colorectal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT06493760 2024-09-19
A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Phase 2 Recruiting
NCT02873195 2024-08-23
Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer
Academic and Community Cancer Research United
Phase 2 Completed
NCT02842580 2024-07-10
HIGH-LIGHT
Federation Francophone de Cancerologie Digestive
Phase 2 Terminated
NCT06148402 2024-05-13
Fruquintinib Plus Camrelizumab and Capecitabine as Salvage Therapy After Progression on FOLFOXIRI-based First-line Treatment in Patients With Unresectable/Metastatic Colorectal Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Recruiting
NCT06234007 2024-03-18
Short-course Radiotherapy Followed by Fruquintinib Plus Adebrelimab and CAPOX in the Full Course Neoadjuvant Treatment of Locally Advanced Rectal Cancer: a Multicenter, Single-arm, Open-label Study
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Recruiting
NCT06192680 2024-01-18
Liposomal Irinotecan and Capecitabine Plus Bevacizumab as Second-line Therapy in Metastatic Colorectal Cancer
Harbin Medical University
Phase 2 Not yet recruiting
NCT05578287 2023-12-07
DETECT
Sun Yat-sen University
Phase 2 Unknown
NCT01776307 2023-11-15
A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
Sumitomo Pharma America, Inc.
Phase 2 Completed
NCT04310176 2023-11-13
REVOLUTION
National Cancer Institute, Naples
Phase 2 Unknown
NCT05799820 2023-05-25
QL1706 Monotherapy or in Combination With Bevacizumab and XELOX as First-line Treatment of Unresectable Advanced or Metastatic CRC
Qilu Pharmaceutical Co., Ltd.
Phase 2 Unknown
NCT05794750 2023-04-06
AK104-IIT-13
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Not yet recruiting
NCT04304209 2023-02-01
Pd1 Antibody Sintilimab ± Chemoradiotherapy for Locally Advanced Rectal Cancer
Sun Yat-sen University
Phase 2 Active not recruiting
NCT05659290 2023-01-06
Alternating Treatment With Fruquintinib and Bevacizumab Plus Capecitabine as Maintenance Therapy After First-Line Treatment in Metastatic Colorectal Cancer
Nanfang Hospital, Southern Medical University
Phase 2 Unknown
NCT00954876 2022-10-20
Study of Capecitabine and Cetuximab as First-Line Therapy in Patients With Metastatic Wild Type Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Colorectal Cancer
Translational Genomics Research Institute
Phase 2 Withdrawn
NCT04733963 2022-07-26
Fruquintinib Plus Capecitabine Versus Bevacizumab Plus Capecitabine as Maintenance Therapy Following First-line Treatment for Metastatic Colorectal Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Unknown
NCT04080843 2022-07-13
ALTER-C-002
Zhejiang University
Phase 2 Completed
NCT05451719 2022-07-12
Fruquintinib Plus Capecitabine Versus Capecitabine as Maintenance Therapy for Metastatic Colorectal Cancer After First-line Chemotherapy
Fudan University
Phase 2 Unknown
NCT01759238 2022-07-01
OLGA
Universitätsklinikum Hamburg-Eppendorf
Phase 2 Terminated
NCT04247984 2022-03-11
A Comparison of mXELIRI Regimen and FOLFIRI Combined Bevacizumab Regimen as First-line Chemotherapy Regimen for Metastatic Colorectal Cancer
ChineseAMS
Phase 2 Completed
NCT04911517 2022-02-23
Neoadjuvant Chemoradiotherapy Plus Tislelizumab Followed by TME for LARC.
Beijing Friendship Hospital
Phase 2 Unknown
NCT00321100 2022-01-12
Combination of Cetuximab, Capecitabine, and Oxaliplatin With or Without Bevacizumab
Fox Chase Cancer Center
Phase 2 Terminated
NCT03050814 2021-12-20
Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00314353 2021-10-06
Study of Bevacizumab Combined With Capecitabine and Either Oxaliplatin or Irinotecan as First Course of Treatment for Patients With Colorectal Cancer That Has Spread Beyond the Colon
NSABP Foundation Inc
Phase 2 Terminated
NCT00640081 2021-09-22
Combination Chemotherapy and Cetuximab as First-Line Therapy in Treating Patients With Advanced and/or Metastatic Colorectal Cancer
Medical Research Council
Phase 2 Completed
NCT02414009 2021-09-09
CAPTEM
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Completed
NCT00104689 2021-02-21
Capecitabine and Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer
UNICANCER
Phase 2 Completed
NCT00423696 2021-02-17
Bevacizumab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery
UNICANCER
Phase 2 Completed
NCT04425564 2020-06-11
Study of Metronomic Capecitabine and Oxaliplatin Versus XELOX in Egyptian Metastatic Colorectal Cancer Patients
National Cancer Institute, Egypt
Phase 2 Completed
NCT00444678 2020-04-03
Cetuximab Plus Biweekly Capecitabine and Oxaliplatin in KRAS Wild Type Metastatic Colorectal Cancer
NYU Langone Health
Phase 2 Completed
NCT00081289 2020-02-27
Neoadjuvant Chemoradiotherapy and Adjuvant Chemotherapy in Treating Patients Who Are Undergoing Surgical Resection for Locally Advanced Rectal Cancer
Radiation Therapy Oncology Group
Phase 2 Completed
NCT02280694 2020-02-12
LDMchemoCRC
HaEmek Medical Center, Israel
Phase 2 Completed
NCT00541112 2020-02-11
Radiation Therapy, Chemotherapy, and Cetuximab Followed by Surgery, Chemotherapy, and Cetuximab in Treating Patients With Locally Advanced or Metastatic Rectal Cancer That Can Be Removed by Surgery
UNICANCER
Phase 2 Terminated
NCT01993472 2020-01-14
AGCRC-013
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Terminated